XML 45 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Merger and Financing (Tables)
 12 Months Ended
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Schedule of Common Stock Outstanding

The following table presents the total Common Stock outstanding immediately after the closing of the Merger:

 

 

  

Number of

Shares

 
Exchange of MURF common stock subject to possible redemption for Conduit Pharmaceuticals Inc. common stock   580 
Exchange of MURF Class A common stock held by MURF Directors for Conduit Pharmaceuticals Inc. common stock   450 
Exchange of MURF Class A common stock held by MURF Sponsor for Conduit Pharmaceuticals Inc. common stock   40,152 
Subtotal - Merger, net of redemptions   41,182 
Issuance of Conduit Pharmaceuticals Inc. common stock in connection with PIPE Financing   20,000 
Exchange of Conduit Pharmaceuticals Limited ordinary shares for Conduit Pharmaceuticals Inc. common stock on the Closing Date   646,264 
Issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes on the Closing Date   3,735 
Issuance of Conduit Pharmaceuticals Inc. common stock to an advisor for services directly related to the Merger   13,000 
Total - Conduit Pharmaceuticals Inc. common stock outstanding as a result of the Merger, PIPE Financing, exchange of Conduit Pharmaceuticals Limited shares for shares of Conduit Pharmaceuticals Inc., issuance of Conduit Pharmaceuticals Inc. common stock to holders of Conduit Pharmaceuticals Limited convertible notes, and advisors.   724,181